Bayer stock gains as FDA approves first Factor XIa inhibitor

Published on 11/10/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock is in focus after the FDA approved Sunharbo for secondary stroke prevention in the United States. The drug opens a new commercial opportunity.

FDA approval strengthens Bayer's drug pipeline

The FDA approved Sunharbo for secondary stroke prevention alongside antiplatelet therapy.
Phase 3 results showed a 26 percent reduction in ischemic strokes with similar major bleeding rates.
U.S. shipments are expected to begin in mid-to-late November, while further market applications remain under review.

Bayer, DE000BAY0017, Illustration mit AI erstellt.

Bayer announced on Tuesday, November 10, 2026, that the U.S. Food and Drug Administration had granted marketing authorization for Sunharbo, the brand name for asundexian. The approval covers adults with a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, in combination with antiplatelet therapy. Bayer published the announcement at 00:15 AM Central European Time and said the product is the first approved Factor XIa inhibitor worldwide.

Bayer said the decision was based on the global Phase 3 OCEANIC-STROKE study, which enrolled 12,327 participants. In the trial, asundexian reduced ischemic strokes by 26 percent when added to antiplatelet therapy. Major bleeding rates were similar between the asundexian and placebo groups.

A new commercial test for Pharmaceuticals

Bayer expects U.S. shipments to start in mid-to-late November, with hospital and pharmacy availability following shortly thereafter. The company said applications in additional markets are under review, while China has already approved the medicine.

The regulatory decision adds a new growth opportunity for Bayer's Pharmaceuticals division, but commercial execution will determine how quickly it contributes to sales and earnings. Uptake, reimbursement and the medicine's safety profile will remain important factors for investors.

Bayer stock traded at 57.04 euros on Lang & Schwarz at 17:05 CET on Tuesday, November 10, 2026, 0.74 percent above the Xetra close of Monday, November 9, 2026. The Xetra reference close was 56.62 euros.